Biologic agent activity in chronic lymphocytic leukemia: A framework for future therapies

Chadi Nabhan*, Neil Dalal, Jayesh Mehta, Neil E. Kay

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.

Original languageEnglish (US)
Pages (from-to)374-386
Number of pages13
JournalLeukemia and Lymphoma
Volume52
Issue number3
DOIs
StatePublished - Mar 1 2011

Keywords

  • Immunotherapeutic approaches
  • chemotherapeutic approaches
  • lymphoid leukemia
  • pharmacotherapeutics
  • signaling therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Biologic agent activity in chronic lymphocytic leukemia: A framework for future therapies'. Together they form a unique fingerprint.

  • Cite this